 Drug Resistance, Viral
"Drug Resistance, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
| Descriptor ID |
D024882
|
| MeSH Number(s) |
G06.225.420 G06.920.225 G07.690.773.984.269.420
|
| Concept/Terms |
Drug Resistance, Viral- Drug Resistance, Viral
- Drug Resistances, Viral
- Antiviral Drug Resistance
- Antiviral Drug Resistances
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Viral".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Viral".
This graph shows the total number of publications written about "Drug Resistance, Viral" by people in this website by year, and whether "Drug Resistance, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 | | 2002 | 2 | 1 | 3 | | 2003 | 4 | 2 | 6 | | 2004 | 2 | 4 | 6 | | 2005 | 4 | 2 | 6 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 2 | 4 | | 2008 | 3 | 2 | 5 | | 2009 | 2 | 1 | 3 | | 2010 | 1 | 4 | 5 | | 2011 | 0 | 4 | 4 | | 2012 | 2 | 3 | 5 | | 2013 | 2 | 0 | 2 | | 2014 | 4 | 5 | 9 | | 2015 | 1 | 4 | 5 | | 2016 | 3 | 2 | 5 | | 2017 | 3 | 3 | 6 | | 2018 | 2 | 1 | 3 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 2 | 2 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2024 | 2 | 0 | 2 | | 2025 | 6 | 2 | 8 | | 2026 | 2 | 5 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.
-
Han WM, Solomon S, Wagner-Cardoso S, Li J, Parvangada A, Sulkowski M, Naggie S, Martin R, Mo H, Maiorova E, Wyles D. Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 (MINMON) Clinical Trial. J Viral Hepat. 2026 Nov; 33(11).
-
Rogg L, Nuñez SA, Mingrone MV, Domingo P, Rolle CP, Güerri-Fernandez R, Estrada V, Lopez M, Hanan N, Ghita GL, Jeffrey JL, Underwood M, Castillo-Mancilla JR, Halliday F, Ezeadi E, Gartland M. Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis. 2026 Oct 28; 83(4):e819-e825.
-
Vyshenska D, Reed JC, Roychoudhury P, Zheng L, Olefsky M, Ritz J, McCarthy C, Saha PT, Hao L, Mills MG, Shea A, Nunley BE, Javan AC, Brooks KM, Nachman S, Eron J, Gandhi RT, Currier J, Fischer WA, Zucker J, Wilkin T, Greninger AL. Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial. Lancet Microbe. 2026 Sep; 7(9):101464.
-
Moeser MJ, Council OD, Long N, Kincer L, Dennis AM, Eron J, Wohl D, Farel CE, Dittmer DP, Pluta L, Nelson J, Mohammadi A, Etemad B, Li JZ, McGann H, Smit E, Clement M, Yau T, Menezes P, Bowman NM, Zhou S, Joseph SB. A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage. J Infect Dis. 2026 Jun 16; 233(6):1005-1014.
-
Stabell AC, Lee S, Park DJ, Lavine CL, Espinosa SM, Baharani VA, Patejak R, Nussenzweig MC, Caskey M, Seaman MS, Bieniasz PD, Hatziioannou T. Diverse paths to broadly neutralizing antibody escape among HIV-1 strains. Nat Microbiol. 2026 Jun; 11(6):1573-1584.
-
Beck IA, Boyce CL, Bishop MD, Oldroyd AR, du Toit L, Saimen A, Ramarope KM, Hitchcock S, du Plessis NM, Mbogo L, Chohan BH, Maheria P, Oyaro P, Knowles K, Zhang Z, Brummel SS, Drain PK, Smith RA, Gottlieb GS, Abuogi L, Patel RC, Farquhar C, Wiznia A, Ruel TD, Rossouw TM, Hawes SE, Frenkel LM. HIV Resistance to Dolutegravir Varies With Coadministered Agents. Clin Infect Dis. 2026 Apr 30; 82(4):592-596.
-
Ombajo LA, Nkuranga J, Penner J, Kamau EW, Ismael N, Munseri P, Ayakaka I, Labhardt N, Wamalwa D, Ramgi P, Chissumba RM, Wagude J, Bakari M, Omodi V, Otieno E, Abuogi L, Patel R, Opondo C, Grint D, King'wara L, Macharia A, Mulwa A, Amoth P. The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol. PLoS One. 2026; 21(3):e0330792.
-
Pasco R, Hayden FG, Meyers LA. Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance. J Infect Dis. 2025 Oct 17; 232(Supplement_3):S299-S308.
-
Rogg L, Underwood M, Hanan N, Castillo-Mancilla JR, Kahl L, Halliday F, Ghita GL, Jeffrey JL, Byrne S, Onodera T, Horton J, Gartland M. Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis. 2025 Oct 06; 81(3):510-520.
-
Scallon AJ, Maheria P, Oyaro P, Thomas KK, Chohan BH, Odhiambo F, Brown E, Ochomo E, Karauki E, Yongo N, Hassan SA, Bishop MD, Beck IA, Boyce C, Frenkel LM, Abuogi L, Patel RC. Clinical, Psychosocial, and Structural Factors Associated with the Detection of HIV Drug Resistance in Children Living with HIV in Kisumu, Kenya: Secondary Analysis of Data from the Opt4Kids Study. Viruses. 2025 Sep 16; 17(9).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|